Lenalidomide: a novel anticancer drug with multiple modalities

Bibliography

• Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-61
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-76
   PubMed Web of Science ®Google Scholar
• Brandenburg NA, Weiss L, Bwire R, et al. Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: Incidence and risk factors. J Clin Oncol 2008;26:7084 [Meeting Abstracts]
   Google Scholar
• Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Zeldenrust S, et al. Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma. J Clin Oncol 2008;26:8525 [Meeting Abstracts]
   Google Scholar
• Rajkumar SV, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi. J Clin Oncol 2008;26:8504 [Meeting Abstracts]
   Google Scholar
• Anderson KC, Jagannath S, Jakubowiak A, et al. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol 2008;26:8545 [Meeting Abstracts]
   Google Scholar
• Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004;6:547-52
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57
   PubMed Web of Science ®Google Scholar
• Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol 2007;19:656-9
   PubMedGoogle Scholar
• Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol 2007;86:301-5
   PubMed Web of Science ®Google Scholar
• Chen J, McMillan NA. Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol Ther 2008;174-9
   PubMedGoogle Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;11:5291-7
   Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-25
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Whitworth A, Bangia N, et al. Lenalidomide-Associated Tumor Flare Reaction Is Manageable in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 2008;26:4851-2
   PubMed Web of Science ®Google Scholar
• Lin TS. Lenalidomide: what is the right dose in CLL? Blood 2008;111:5268
   PubMedGoogle Scholar
• Coleman M, Martin P, Ruan J, et al. The THRIL (thalidomide [T], rituximab [R], and lenalidomide [L]) regimen for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma: daily alternating IMiDs and rituximab maintenance. J Clin Oncol 2008;26:7079 [Meeting Abstracts]
   Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II study. J Clin Oncol 2006;24:5343-9
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37
   PubMed Web of Science ®Google Scholar
• James DF, Betty MR, Mosadeghi R, Kipps TJ. Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. Blood 2007;110:A916-7
   Google Scholar
• Wang M, Fayad L, Hagemeister F, et al. A Phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007;25:8030 [Meeting Abstracts]
   Google Scholar
• Czuczman MS, Reeder CB, Polikoff J, et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:8509 [Meeting Abstracts]
   Google Scholar
• Zhang L, Schafer P, Muller G, et al. The ratio of cyclin D1/p21kip baseline gene expression and SPARC gene expression can be potential predictors of non-Hodgkin's lymphoma (NHL) patient response to lenalidomide therapy. J Clin Oncol 2008;26:22150 [Meeting Abstracts]
   Google Scholar
• Witzig TE, Vose JM, Justice G, et al. Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin's lymphoma. J Clin Oncol 2008;26:8573 [Meeting Abstracts]
   Google Scholar
• Blum WG, Andritsos LA, Johnson AJ, et al. Preliminary results of a Phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose. J Clin Oncol 2008;26:7075 [Meeting Abstracts]
   Google Scholar
• Garcia JA, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a Phase II trial. J Clin Oncol 2008;26:5143 [Meeting Abstracts]
   Google Scholar
• Ain KB, Lee C, Holbrook KM, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol 2008;26:6027 [Meeting Abstracts]
   Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-55
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406-11
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703
   PubMed Web of Science ®Google Scholar
• Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl 1):I107-13
   PubMed Web of Science ®Google Scholar
• Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-15
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32
   PubMed Web of Science ®Google Scholar
• Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res 2005;25:604-16
   PubMedGoogle Scholar
• Jones E, hm-Vicker M, Golgher D, Gallimore A. CD25+ regulatory T cells and tumor immunity. Immunol Lett 2003;85:141-3
   PubMedGoogle Scholar
• Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004;6:745-51
   PubMed Web of Science ®Google Scholar
• Galustian C, Klaschka DC, Meyer B, et al. Lenalidomide (Revlimid(R), CC-5013) and ActimidTM (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo AACR 2006:1147 [Meeting Abstracts]
   Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2008 (In Press)
   PubMedGoogle Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61
   PubMed Web of Science ®Google Scholar
• Diederichsen ACP, Zeuthen J, Christensen PB, Kristensen T. Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer 1999;35:721-6
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, et al. Increased Populations of Regulatory T Cells in Peripheral Blood and Tumor-Infiltrating Lymphocytes in Patients with Gastric and Esophageal Cancers. Clin Cancer Res 2003;9:4404-8
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. PNAS 2005;102:18538-43
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4+CD25high FOXP3+ regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639-46
   PubMed Web of Science ®Google Scholar
• Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1788-93
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid((R)) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-59
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells. Clin Cancer Res 2008;14:4650-7
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Schafer P, et al. Effect of lenalidomide and pomalidomide combined with IgG1-isotype antibodies on antibody-dependent cellular cytotoxicity (ADCC) via cytokine signaling and effector cell granzyme B and FasL expression. J Clin Oncol 2008;26:3058 [Meeting Abstracts]
   Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203
   PubMed Web of Science ®Google Scholar
• Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, et al. Enhancement of ligand dependent activation of human Natural Killer T cells by Lenalidomide: Therapeutic Implications. Blood 2006;108:2005-10
   Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Karali M, Kokkonouzis I, et al. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk Lymphoma 2003;44:937-48
   PubMed Web of Science ®Google Scholar
• Xu JL, Lai R, Kinoshita T, et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002;55:530-4
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo Br J Haematol 2008;140:36-45
   PubMed Web of Science ®Google Scholar
• Heere-Ress E, Boehm J, Thallinger C, et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol 2005;125:201-6
   PubMedGoogle Scholar
• Downs LS Jr, Rogers LM, Yokoyama Y, Ramakrishnan S. Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer. Gynecol Oncol 2005;98:203-10
   PubMedGoogle Scholar
• Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63
   PubMed Web of Science ®Google Scholar
• Fujita K, Asami Y, Tanaka K, et al. Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta. Histochem Cell Biol 2004;122:27-33
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Wang J, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003;23:2481-7
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Wang J, et al. Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. Int J Mol Med 2003;11:785-90
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001;115:605-8
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Segarra M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004;26:145-8
   PubMedGoogle Scholar
• Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166-72
   PubMed Web of Science ®Google Scholar
• Mangiameli DP, Blansfield JA, Kachala S, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Trans Med 2007;5:38
   PubMedGoogle Scholar
• McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997;49:123-31
   PubMed Web of Science ®Google Scholar
• Settles B, Stevenson A, Wilson K, et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy le grand) 2001;47:1105-14
   PubMed Web of Science ®Google Scholar
• Onat D, Stahl W, Sies H. Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344). Biochem Pharmacol 2001;62:1081-6
   PubMedGoogle Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6
   PubMed Web of Science ®Google Scholar